---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040643"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:30:56.864505+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q2 revenue $117.3M (-3% YoY); withdraws FY2023 guidance on Medicare LCDs

## Summary
- Net revenue of $117.3M, down 3% YoY from $121.4M; net income $5.3M vs $8.7M.
- Adjusted net income $6.1M, adjusted EBITDA $15.4M; both down YoY.
- Withdrew FY2023 guidance due to Medicare LCDs from Novitas, First Coast Services, CGS limiting DFU/VLU coverage to only Apligraf and Dermagraft effective Sept 17, 2023.
- Cash and equivalents $89.5M, debt $69.0M as of June 30.
- Company engaging with relevant parties regarding LCDs; uncertain impact on revenue outlook.

## SEC filing metadata
- accession: 0000950170-23-040643
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017023040643/0000950170-23-040643-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017023040643/orgo-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040643
- JSON: https://secwatch.observer/filing/0000950170-23-040643.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040643.txt

## Key facts
- Earnings Releases
  Organogenesis Holdings Inc. reported the fiscal second quarter ended June 30, 2023 results: revenue $117.3 million, net income $5.3 million, or $0.04 per share, EPS $0.04 per share.
  - Period: the fiscal second quarter ended June 30, 2023
  - Revenue: $117.3 million
  - Net income: $5.3 million, or $0.04 per share
  - EPS: $0.04 per share
  - Result: reported results
  source text: & Sports Medicine markets, today reported financial results for the second quarter ended June 30th, 2023. Second Quarter 2023 Financial Results Summary: • Net revenue of $117.3 million for the second quarter of 2023, a decrease of $4.1 million compared to net revenue of $121.4 million for the second quarter of 2022. Net revenue for the second quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661181/000095017023040643/0000950170-23-040643-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.